drugset / Trial / NCT06651021
A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants
NaSingle-groupOpen-labelTreatment
Summary
This study is intended to evaluate the PK, safety, and tolerability of balcinrenone/dapagliflozin given as a single dose capsule to healthy Chinese participants.
Timeline
- Start
- 2024-10-21
- Primary completion
- 2024-10-28
- Completion
- 2024-10-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 10 mg | — |
| Subject | balcinrenone | Small molecule | 40 mg | — |
Indications
No indication recorded.